Will Making the HPV Vaccine Available at Mayo Clinic Express Care with Use of Electronic Point of Care Reminder Improve Overall Vaccination Rates Among an Empaneled Adolescent Population?


About this study

The purpose of this study is to determine if a medical record prompt at the time of a medical consult will help to address lapses in routine immunizations, including the HPV vaccine.



Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:       

  • ECH (Family Medicine, Community Pediatric and Adolescent Medicine, Primary Care Internal Medicine) empaneled
  • Minnesota Resident
  • Patients under 18 must have parental or guardian permission
  • Females age 9-26
  • Males age 9-21- up to 26 if a male who has sex with males or immunocompromised (such as HIV)

Exclusion Criteria: 

  • Received a stem cell transplant or bone marrow transplant within the last 6 months.
  • Severe, life-threatening allergic reaction to a dose of HPV vaccine
  • Severe, life threatening allergy to any component of HPV vaccine
  • Hypersensitivity to yeast
  • Pregnant women
  • Severely ill
  • Receiving chemotherapy or radiation therapy

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Amanda Meyer, APRN, C.N.P., D.N.P.

Closed for enrollment

More information


Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions